Free Trial

Adverum Biotechnologies Q1 2023 Earnings Report

Adverum Biotechnologies logo
$4.37 -0.24 (-5.21%)
As of 04:00 PM Eastern

Adverum Biotechnologies EPS Results

Actual EPS
-$2.90
Consensus EPS
-$3.00
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Adverum Biotechnologies Revenue Results

Actual Revenue
$3.60 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adverum Biotechnologies Announcement Details

Quarter
Q1 2023
Time
N/A
Remove Ads

Adverum Biotechnologies Earnings Headlines

While Markets Slide, These "Genesis Cog" Trades Are Up Double-Digits
While most investors are struggling in today's volatile market, a small group of traders are quietly booking consistent gains. Just last week, our Genesis Cog subscribers captured an 11.51% gain shorting JEF, another 8.57% on CAKE, and 4.78% on RJF—all while the broader indexes continued their downward trend.
Adverum Biotechnologies initiates ARTEMIS study
See More Adverum Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adverum Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adverum Biotechnologies and other key companies, straight to your email.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ:ADVM), a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

View Adverum Biotechnologies Profile

More Earnings Resources from MarketBeat